Zealand Pharma presents preclinical data on GIP analogue ZP-6590

Nov. 9, 2022

Researchers from Zealand Pharma A/S have presented details on their investigation of ZP-6590 as an antiobesity and antiemetic drug in mice.

BioWorld Science Conferences Endocrine/metabolic

Today's news in brief

BioWorld

BioWorld briefs for Nov. 6, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 6, 2024.

Regulatory actions for Oct. 31, 2024

BioWorld

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...

Australia reimburses Vazkepa a decade after US approval

BioWorld

For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

Sanofi bets on Resalis’ oligonucleotide RES-010 for obesity

BioWorld

After missing out on the glucagon-like peptide 1 obesity market, Sanofi SA is prospecting for next-generation drugs and is making a strategic equity investment in...